Get the Stockscreener App
40.63
0.53%
0.2151
Apellis Pharmaceuticals Inc stock is traded at $40.63, with a volume of 3.91M.
It is up +0.53% in the last 24 hours and up +102.41% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
See More
Previous Close:
$40.41
Open:
$40.43
24h Volume:
3.91M
Relative Volume:
0.84
Market Cap:
$5.19B
Revenue:
$1.00B
Net Income/Loss:
$22.39M
P/E Ratio:
328.95
EPS:
0.1235
Net Cash Flow:
$45.01M
1W Performance:
+137.70%
1M Performance:
+102.41%
6M Performance:
+66.76%
1Y Performance:
+103.42%
1-Day Range:
$40.41
$40.69
1-Week Range:
$40.22
$40.69
52-Week Range:
$16.10
$40.69
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.62 | 5.17B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
434.55 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.54 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.40 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.94 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.96 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold" - MarketBeat
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry - Sahm
Apellis surges on $5.6B buyout deal with Biogen - MSN
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
Apellis Pharmaceuticals (APLS): Mizuho Raises Price Target Amids - gurufocus.com
Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by Jefferies Financial Group - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by William Blair - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to Hold Rating by Cantor Fitzgerald - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Hold Rating by Citigroup - MarketBeat
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate - ChartMill
Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal - eHealth Magazine
Roth/MKM downgrades Apellis stock rating on Biogen acquisition - Investing.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) - Sahm
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - qz.com
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
APLS: Barclays Raises Price Target for Apellis Pharmaceuticals | - gurufocus.com
APLS: JP Morgan Downgrades Apellis Pharmaceuticals, Raises Price Target | APLS Stock News - gurufocus.com
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst Revisions - Yahoo Finance
Apellis Pharmaceuticals, Inc. (APLS) Stock Forecasts - Yahoo Finance
JPMorgan Chase & Co. Reaffirms Neutral Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Watch Biogen Buys Apellis for $5.6B to Expand Kidney Drugs - Bloomberg.com
American Biogen bought assets of Apellis Pharmaceuticals for $5.6 billion - AKM.RU
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com Canada
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Apellis Pharmaceuticals (NASDAQ:APLS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
APLS Downgraded by Raymond James to Market Perform | APLS Stock News - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Sharp Recent Share Price Surge - simplywall.st
Worldwide Healthcare Trust PLCBiogen, Inc. to acquire WWH portfolio company, Apellis Pharmaceuticals, Inc. - bolsamania.com
Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Market Perform" Rating from Raymond James Financial - MarketBeat
Mizuho raises Apellis stock price target to $41 on Biogen deal - investing.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - pharmexec.com
APLS Downgraded by Citigroup: Target Price Lowered to $41.00 | A - GuruFocus
This PPG Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - Yahoo Finance
Apellis Pharmaceuticals (NASDAQ:APLS) Given Neutral Rating at Citigroup - MarketBeat
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):